INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Oncology & Hematology Patient Engagement Publication Perspective
Video Journal of Biomedicine | Publication Perspective
Video Journal of Biomedicine (2022) doi: 10.2217/vjbm-2022-0003

MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibitor, such as tepotinib, an oral, highly selective, potent MET tyrosine kinase inhibitor, may overcome METamp-driven resistance.

In this video, Professor Egbert Smit (Netherlands Cancer Institute, Amsterdam) discuss their recent publication, ‘INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance’, published in Future Oncology.

Original article:

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Egbert F Smit, Christophe Dooms, Jo Raskin et al.

Future Oncology 18(9) (2021) DOI: 10.2217/fon-2021-1406